Early Phase Development

Codex DNA Aims to Accelerate Virus Research with Full-Length Synthetic Genome for SARS-CoV-2 Delta Variant

September 30, 2021

In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.

FDA Removes Clinical Hold on Phase I/II Study of Angelman Syndrome Treatment

September 29, 2021

GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.

Researchers from the University of California Riverside Investigate Plant-Based mRNA Vaccines

September 17, 2021

UCR scientists are researching whether a plant-based messenger RNA vaccine can be created and aim to eliminate the need for the refrigeration of mRNA vaccines during transport and storage.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

September 09, 2021

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

FSD Pharma to Acquire Lucid Psycheceuticals

August 27, 2021

FSD Pharma has entered a definitive agreement to acquire all of the issued and outstanding shares of Lucid Psycheceuticals for approximately US$9 million (CAD$11.3 million) in FSD Pharma stock.

Investigational Radiopharmaceutical for the Treatment of Bone Cancer Receives FDA Clearance of IND

August 27, 2021

FDA has cleared QSAM Biosciences’s IND application for Samarium-153 DOTMP (CycloSam).

Nanoform, Boehringer Ingelheim Collaborate on Pre-Clinical Development Projects

August 05, 2021

Nanoform and Boehringer Ingelheim have executed a master services agreement in relation to pre-clinical development projects.

Imugene and Celularity to Develop Solid Tumor Treatment

August 05, 2021

A research collaboration will combine Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy.

Janssen Collaborates with BioMedX in Autoimmunity and Drug Delivery Research

August 04, 2021

BioMed X Institute and Janssen Research & Development to start two new research programs in the field of autoimmune diseases and drug delivery.

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center

November 05, 2020

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.